19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2525



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Scoliosis Screenings Can Help Catch Spine Problem EarlyArthritis Can Strike ChildrenPlan an Allergy-Safe Halloween for Your ChildHappier Mealtimes, Healthier Eating for KidsAAP Releases List of Often-Unnecessary TestsUSPSTF Recommends Counseling Youth on Sun Protection BehaviorChildhood Obesity Up Worldwide Almost 10-Fold Over 4 DecadesStart Skin Cancer Prevention Early, Health Experts SayHealth Tip: Getting Enough SleepSurviving Congenital Heart Disease as Child Not a Ticket to Good HealthHealth Tip: Children and Screen UseHealth Tip: Suggestions for a Healthy HalloweenMaking Halloween a Treat for Kids With DiabetesHealth Tip: Learn Symptoms of Childhood SinusitisChildhood 'Growth' Tests Not Always NecessaryMore U.S. Measles Cases From No Vaccine vs. Imported DiseaseMeasles Making a Comeback in the United StatesReassuring Kids After Another Senseless TragedyBilingual Kids Learn New Languages BetterGirls' Sports-Related Concussions May Last Twice As LongTeens Mixed Up With the Law May Fall Through Medicaid CracksLooking at Laughter for Clues to Anti-Social BehaviorHigh Blood Pressure in Pregnancy May Boost Child's Obesity RiskDon't Let Your Kids Get Sidelined With Sports-Related Infections'Off-Roading' Threat May Lurk in the AirHealth Tip: Identifying Chicken PoxCould Pests, Dust Lower Kids' Odds for Asthma?When a Cold or Flu Strikes a Family MemberBooze Often Glorified On YouTube VideosInflammatory Bowel Disease May Raise Cancer Risk in KidsKids' Colds Linked to Asthma, Lung Problems LaterAAP: Few Doctors Provide Firearm Injury Prevention Info in ERDoctors Eye the Danger From 'Nerf' GunsParents Say Schools Don't Help Kids With Mental Health, Chronic DiseaseIt's a Food Allergy! Where's the School Nurse?Big Rise in Hospitalized Kids With Opioid Side EffectsAAP: Opioid Dependence/Abuse Public Health Issue for ChildrenGolf Carts' Use Is Spreading, and So Is Danger to KidsState Laws Have Big Impact on Kids' Gun InjuriesHealth Tip: On Kids and Pets'Microbiomes' May Hold Key to Kids' Ear InfectionsHurricanes May Have Longer-Lasting Impact on KidsHeath Tip: Getting Rid of Head LiceState Laws Curb Kids' Injuries Tied to Off-Road VehiclesBrown-Bagging It? Think Outside the BoxVaccine Campaign in Poor Countries to Save 20 Million LivesGuinea Pigs Harbor a Hidden Health HazardFor City Kids With Asthma, Nearby Green Space Is KeyEarly Respiratory Infections Tied to Celiac in High-Risk ChildrenHealth Tip: Fuel Your Child With a Good Breakfast
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

Direct-Acting Antivirals Approved for Children 12+ With HCV


HealthDay News
Updated: Apr 10th 2017

new article illustration

MONDAY, April 10, 2017 (HealthDay News) -- The U.S. Food and Drug Administration has approved two drugs to treat hepatitis C virus (HCV) infection in children aged 12 and older.

Sovaldi (sofosbuvir) and Harvoni (ledipasvir, sofosbuvir) are the first direct-acting antiviral treatments approved for children and adolescents with HCV, the agency said in a news release Friday.

The two approvals provide pediatric treatment options for six major genotypes of HCV: Harvoni is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 1, 4, 5, or 6 infection without cirrhosis or with mild cirrhosis. Sovaldi in combination with ribavirin is indicated for the treatment of pediatric patients ≥12 years or weighing ≥35 kg with HCV genotype 2 or 3 infection without cirrhosis or with mild cirrhosis.

In clinical studies, the most common side effects of both drugs were fatigue and headache. Health care professionals should screen all patients for evidence of current or prior hepatitis B virus infection before starting treatment with Harvoni or Sovaldi, the agency advised.

"These approvals will help change the landscape for HCV treatment by addressing an unmet need in children and adolescents," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

Harvoni and Sovaldi are marketed by Gilead Sciences, in Foster City, Calif.

More Information